Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

about

Advances on systemic treatment for lung neuroendocrine neoplasms.

P2860

Q55375491-F3EBECC8-5090-49AE-BC87-44859D1BE995

P2860

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Item

http://www.wikidata.org/entity/Q40202162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Everolimus with paclitaxel and ...... a multicenter phase II trial.

@en

type

Item

label

Everolimus with paclitaxel and ...... a multicenter phase II trial.

@en

prefLabel

Everolimus with paclitaxel and ...... a multicenter phase II trial.

@en

P1476

Everolimus with paclitaxel and ...... : a multicenter phase II trial

@en

P2093

C Grohé

http://www.w3.org/2001/XMLSchema#string

C Kropf-Sanchen

http://www.w3.org/2001/XMLSchema#string

C Sieder

http://www.w3.org/2001/XMLSchema#string

D Ukena

http://www.w3.org/2001/XMLSchema#string

I Nimmrich

http://www.w3.org/2001/XMLSchema#string

J Kollmeier

http://www.w3.org/2001/XMLSchema#string

J von Pawel

http://www.w3.org/2001/XMLSchema#string

M Serke

http://www.w3.org/2001/XMLSchema#string

M Thomas

http://www.w3.org/2001/XMLSchema#string

P A Schnabel

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR: from growth signal integration to cancer, diabetes and ageing

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment.

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy

mTOR inhibition improves immune function in the elderly.

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

P304

1898-1902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX268

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Petros Christopoulos

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28535181

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

about

P2860

P2860

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921